Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine

European Journal of Cancer

Volumn 34, Issue 13, 1998, Pages 2101-2106

  Arrieta, O ^b   Guevara, P ^b   Reyes, S ^b   Ortiz, A ^a   Rembao, D ^b   Sotelo, J ^b  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b NONE

Author keywords

Angiogenesis; Cancer therapy; Glioblastoma; Growth factors; Protamine

Indexed keywords

CARMUSTINE; GROWTH FACTOR; NITROSOUREA; PROTAMINE; SURAMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; MITOSIS INDEX; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR VOLUME; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARMUSTINE; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GLIOBLASTOMA; GLIOMA; HEPARIN ANTAGONISTS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTAMINES; RATS; RATS, WISTAR; SURAMIN;

EID: 0032403589     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00244-5     Document Type: Article

References (45)

1. 1. Black PM. Brain tumours. N Engl J Med 1991, 342, 1471-1476.
2. 2. Plate K, Risau W. Angiogenesis in malignant gliomas. Glia 1995, 15, 339-347.
3. 3. Forsyth PAJ, Cairncross JG. Treatment of malignant glioma in adults. Current Opin Neurol 1995, 8, 414-418.
4. 4. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995, 333, 1757-1763.
5. 5. Harris AL. Antiangiogenesis for cancer therapy. Lancet 1997, 349 (Suppl. II), 13-15.
6. 6. Eppenberger AD, Muller H. Growth factor receptors and their ligands. J Neuro-oncol 1994, 22, 249-254.
7. 7. Glick RP, Unterman TG. Radioimmunoassay of insulin-like growth factor I and II in the cerebrospinal fluid of patients with pituitary and other central nervous system tumors. Neurosurgery 1995, 36, 556-563.
8. 8. Weiner HL. The role of growth factor receptors in central nervous system development and neoplasia. Neurosurgery 1995, 37(2), 179-194.
9. 9. Hermansson M, Funa K, Hartman M, et al. Platelet-derived growth factor and its receptors in humans gliomas tissue; expression of RNAm and protein suggest the presence of autocrine and paracrine loops. Cancer Res 1992, 52, 3213-3219.
10. 10. Morrison RS, Yamaguchi F, Bruner JM, Tang M, McKeehan W, Berger MS. Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. Cancer Res 1994, 54, 2794-2799.
11. 11. Samoto K, Ikezaki K, Ono M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 1995, 55, 1189-1193.
12. 12. Strugar JG, Criscuolo GR, Rothbart D, Harrington WN. Vascular endothelial growth/permeability factor expression in human glioma specimens: correlation with vasogenic brain edema and tumor-associated cysts. J Neurosurg 1995, 83, 682-689.
13. 13. Takano S, Yoshihiko Y, Shinichi K, et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 1996, 56, 2185-2190.
14. 14. Raines EW, Bowen-Pope DF, Ross R. Platelet-derived growth factor. In Sporn MB, Roberts AB, eds. Peptide Growth Factors and their Receptors, Vol. 1. New York, Springer, 1991, 208-209.
15. 15. Huang JS, Nishimura J, Huang SS, Deuel TF. Protamine inhibits platelet derived growth factor receptor activity but not epidermal growth factor activity. J Cell Biochem 1984, 26, 205-220.
16. 16. Majerus PW, Broze GJ, Miletich JP, Tollefsen DM. Anticoagulant, thrombolitic and antiplatelet drug. In Hardman JG, Limbird LE, Molinoff LE, Ruddon RW, Goodman A, eds. The Pharmacological Basis of Therapeutics, Vol. II., 9th edn. Mexico, McGraw-Hill, 1996, 1429.
17. 17. Fenstermarker RA, Pootic E, Bonfild TL, et al. A cationic region of the platelet-derived growth factor (PDGF) A-chain (Arg 159-Lys 160-Lys 161) is required for receptor binding and mitogenic activity of the PDGF-AA homodimer. J Biol Chem 1993, 268, 10482-10489.
18. 18. Sato Y, Rifkin DB. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol 1988, 107(3), 1199-1205.
19. 19. Shofield PN, Granerus M, Lee A, Ektrom TJ, Engstrom W. Concentration-dependent modulation of basic fibroblast growth factor action on multiplication and locomotion of human teratocarcinoma cells. FEBS Lett 1992, 298, 154-158.
20. 20. Boensch C, Kuo MD, Connolly DT, Huang SS, Huang JS. Identification, purification, and characterization of cell-surface retention sequence-binding proteins from human SK-Hep cells and bovine liver plasma membranes. J Biol Chem 1995, 270(4), 1807-1816.
21. 21. Vaisman N, Gospodarowicz D, Neufeld G. Characterization of the receptors for vascular endothelial growth factor. J Biol Chem 1990, 265, 19461-19466.
22. 22. Takano S, Stephen G, Engelhard H, Tsanaclis AM, Brem S. Suramin inhibits glioma cell proliferation in vitro and the brain. J Neuro-Oncol 1994, 21, 189-201.
23. 23. La Rocca RV, Stein CA, Danesi R, Cooper MR, Uhrich M, Myers CE. A pilot study of suramin in the treatment of metastatic renal carcinoma. Cancer 1991, 67, 1509-1513.
24. 24. La Rocca RV, Stein CA, Myers CE. Suramin: prototype of new generation of antitumor compounds. Cancer Cells 1990, 2, 106-115.
25. 25. Stein CA, La Rocca RV, Thomas R, McAtee N, Myers CE. Suramin: an anticancer drug with unique mechanism of action. J Clin Oncol 1989, 7, 499-508.
26. 26. Myers CM, Cooper M, Stein C, et al. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 1992, 10, 881-889.
27. 27. Benda P, Lightbody J, Sato G, Levine L, Sweet W. Differentiated rat glial cell strain in tissue culture. Science 1968, 161, 370-371.
28. 28. Barker M, Hoshino T, Gurcay O, Wilson CB, Nielsen SL, Downie R. Development of an animal brain tumor model and its response to therapy with 1,3 (2-chloroethyl)-1-nitrosourea. Cancer Res 1973, 33, 976-986.
29. 29. Larson RE, Rail DP. A study of the toxicity of 1,3-bis/2chloroethyl)-1-nitrosourea (BCNU, NSC-409962). Pharmacologist 1965, 7, 180.
30. 30. Tamayko M, Reynolds P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989, 24, 148-154.
31. 31. Brow WC, Campbell JL. Interaction of proliferating cell nuclear with yeast DNA polymerase delta. J Biol Chem 1993, 268, 21706-21710.
32. 32. Garcia R, Coltrera MD, Gown AM. Analysis of proliferative grade using anti PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Am J Pathol 1989, 134, 733-739.
33. 33. Flanagan MF, Fujii AM, Colan SD, Flanagan RG, Lock JE. Myocardial angiogenesis and coronary perfusion in left ventricular pressure-overload hypertrophy in the young lamb. Evidence for inhibition with chronic protamine administration. Circ Res 1991, 68, 1458-1470.
34. 34. Kersten JR, Warltier DC. Modulation of coronary collateral angiogenesis: a canine model of neovascularization induced by chronic ischemia. J Card Surg 1995, 10(4 pt 1), 354-357.
35. 35. Kersten JR, Pagel PS, Warltier DC. Protamine inhibits coronary collateral development in canine model of repetitive coronary occlusion. Am J Physiol 1995, 268, H720-H728.
36. 36. Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis. Nature 1982, 297, 307-312.
37. 37. Foschi D, Corsi F, Radaelli E, Trabucchi E. Inhibition of inflammatory angiogenesis in rats by loco-regional administration of hydrocortisone and protamine. Agents Actions 1994, 42, 40-43.
38. 38. Robertson EN, Discafani CM, Downs EC, et al. A quantitative in vivo mouse model used to assay inhibitors of tumor-induced angiogenesis. Cancer Res 1991, 51, 1339-1344.
39. 39. Jackson CL, Giles I, Knop A, Nethery A, Schrieber L. Sulfated polysaccharides are required for collagen-induced vascular tube formation. Exp Cell Res 1994, 215(2), 294-302.
40. 40. Huang YQ, Li JJ, Nicolaides A, Zhang WG, Friedman-Kien AE. Increased expression of fibroblast growth factors (FGFs) and their receptor by protamine and suramin on Kaposi's sarcoma-derived cells. Anticancer Res 1993, 13, 887-890.
41. 41. Sugahara K, Nakamura M, Nagisa J, et al. Regulation of serum glycosaminoglycan sulfotransferase activities: inhibition by sulfated glycosaminoglycans and activation by polyamines and basic peptides including a polylysine-containing segment of the c-Ki ras 2 protein. J Biochem Tokyo 1989, 106, 910-919.
42. 42. Liebman HA, Comenzo R, Allen ST, Dilorio JM. A glycosaminoglycan inhibitor of thrombin: a new mechanism for abnormal hemostatic assays in cancer. Am J Hematol 1991, 38, 24-29.
43. 43. Bochkov VN, Tkachuk VA, Philippova MP, Stambolsky DV, Buhler FR, Resink TJ. Ligand selectivity of 105kDa and 130kDa lipoprotein-binding proteins in vascular-smooth-muscle-cell membranes is unique. Biochem J 1996, 317, 297-304.
44. 44. Hakim TS, Picone A, Oleary CE, Camporesi EM. Protamine-induced pulmonary venoconstriction in heparinized pigs. Anesth Analg 1995, 81, 38-43.
45. 45. Baraka A, Choueiry P, Taha S, et al. Hydrocortisone pretreatment for attenuation of protamine-induced adverse hemodynamic reactions. J Cardiothorac Vasc Anesth 1995, 9, 481-482.